FOURKITES
18.5.2022 10:02:11 CEST | Business Wire | Press release
Philippe Salles has been appointed FourKites ’ Vice President of Strategic Solutions (Ocean), bringing a wealth of experience to this booming area of the company’s business.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220518005080/en/
“I’m delighted to be joining FourKites,” says Philippe, who brings experience from CMA CGM, INTTRA and maritime research and consultancy firm Drewry. “Visibility has been ocean shippers’ top priority for decades, and today’s real-time visibility platforms have completely changed the game. In addition to its market-leading machine learning-driven platform, FourKites understands that industry mindset and professionalism are as important as the technology itself. We need to provide shippers with a long-term strategic vision for their supply chain to make them resilient and collaborative.”
Philippe is an industry veteran with a detailed understanding of current supply chain issues. In his new role at FourKites, he will work closely with FourKites shippers and carriers to support them as they execute the change management needed to improve end-to-end supply chain visibility. Moreover, he will accelerate time to value for FourKites users by removing operational pain points and maximising the effectiveness of the systems they use.
“Philippe has a rare depth of experience, especially when it comes to evolving some of the traditional areas of ocean shipping with new technology,” says Mathew Elenjickal, FourKites Founder and CEO. “His network, the trust he's built up in the industry and his expertise in supply chain management will be invaluable to our customers as we continue to drive innovation in ocean visibility.”
FourKites sees unprecedented ocean momentum
Salles’ appointment is the latest leap forward in FourKites’ momentum in supply chain visibility for seagoing container traffic. FourKites now tracks 98% of global ocean container traffic across more than 270 lanes and 120 carriers, and covers every container port in North America and all major ports in Europe.
Over the last 12 months, the company has seen:
- 79% growth in the number of customers using supply chain visibility for international shipments, with a 23% jump in Q1 2022 alone
- 215% growth in the volume of seagoing freight that it tracks, with a 190% increase in ocean shipments in EMEA
- 16% growth in the number of ports tracked in EMEA, now totalling coverage of 239 ports in the region and 804 ports globally
In the last quarter, FourKites signed a number of new ocean customers, including Cardinal Health, Arizona Tile, LyondellBasell, McCain Foods, Roehm, Rove Concepts and Yamaha Motors, among many others.
LyondellBasell, to take one example, is a top-10 global chemicals producer with operations around the world. The company has been a FourKites customer since 2018, when it began tracking shipments across all modes of transport in North America. Based on its success to date with the FourKites platform, the company extended its contract with FourKites in Q1 2022 to track multimodal shipments in Europe.
“Global shippers love FourKites’ Dynamic OceanSM platform because it addresses the full spectrum of shipping issues,” says Philippe. “And the company’s proprietary Dynamic ETA® technology provides estimated times of arrival that are 20% to 40% more accurate than carrier-generated figures. That’s important because timing errors can add significantly to costs.”
FourKites’ Dynamic Ocean addresses the full spectrum of ocean shipping issues through advanced document management and collaboration features; state-of-the-art real-time tracking capabilities, including highly accurate predictive ETAs ; and comprehensive multimodal visibility from port to door, including the yard, so shippers can identify and manage the root causes of escalating fees.
About FourKites
Leading global supply chain visibility platform FourKites® extends visibility beyond transportation into yards, warehouses, stores and beyond. Tracking more than 2.5 million shipments daily across road, rail, ocean, air, parcel and courier, and reaching more than 200 countries, FourKites combines real-time data and powerful machine learning to help companies digitise their end-to-end supply chains. More than 1,000 of the world’s most recognised brands — including 9 of the top-10 CPG and 18 of the top-20 food and beverage companies — trust FourKites to transform their business and create more agile, efficient and sustainable supply chains. To learn more, visit https://www.fourkites.com/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220518005080/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
